Key Takeaways
- Engineers at UC San Diego developed antifungal nanoparticles that target Candida albicans, significantly reducing fungal infections in mice.
- The nanoparticles use human macrophage membranes, helping them evade the immune system while enhancing natural defenses.
- Treatment led to lower fungal levels in organs and improved survival rates in infected mice, indicating potential for future use in preventing infections.
New Approach to Combatting Fungal Infections
Tiny particles derived from human immune cell membranes show promise in battling increasingly resistant fungal infections. Researchers at the University of California San Diego have engineered antifungal nanoparticles that specifically target Candida albicans, a common fungus responsible for various infections, including life-threatening bloodstream conditions.
Led by Liangfang Zhang, a professor at the UC San Diego Jacobs School of Engineering, the research was detailed in the journal Cell Biomaterials. Current antifungal medications primarily target specific fungal cell components, often losing efficacy due to evolving resistance. In contrast, the new nanoparticles physically damage fungal cells while simultaneously boosting the body’s immune response.
To create these nanoparticles, the team isolated the outer membranes of macrophages—immune cells that act as a first line of defense against infections. These membranes were broken into tiny pieces and attached to disc-shaped nanoparticles made from biodegradable polymer. By utilizing real macrophage membranes, the nanoparticles retain proteins that recognize and attack fungal cells, allowing them to effectively mimic the action of immune cells and evade immune responses.
A key advantage of the macrophage membranes is their receptors that naturally recognize Candida. This enables the nanodiscs to attach to fungal cells convincingly. Once they bind, the nanodiscs weaken the fungi’s protective outer membranes, creating openings that lead to cell content leakage and ultimately, cell death. This method reduces the risk of fungal resistance, as it does not target specific molecules.
The diminutive size of the nanodiscs—approximately 10 to 20 nanometers—allows them to interact directly with fungal membranes, a task that full-sized macrophages cannot perform. Traditional macrophages engulf fungi, but Candida has developed survival strategies that can lead to infection spread. By damaging fungal cells, the nanodiscs make them more susceptible to clearance by macrophages.
Further advantages of the nanodiscs include reversing Candida’s suppression of macrophage-produced antifungal chemicals and preventing the formation of biofilms, which protect fungi from treatments and immune responses. The treatment showed significant efficacy in mice with severe bloodstream infections caused by Candida, resulting in reduced fungal presence in vital organs such as the heart and kidneys, alongside improved survival rates. Some treated mice exhibited complete survival.
Additionally, the nanoparticles were effective when administered prior to infection, hinting at their potential use in preventive strategies against fungal infections. Future research aims to evaluate the antifungal effectiveness of these cellular nanodiscs against a wider array of pathogenic fungi.
This innovative approach offers new hope in the ongoing fight against fungal infections that continue to challenge medical treatments.
The content above is a summary. For more details, see the source article.